Noxopharm Limited announced that research from its inflammation-related Sofra preclinical program will be presented orally at the upcoming 15th International Congress on Systemic Lupus Erythematosus (LUPUS 2023). The event will be held in Seoul from 17-20 May and will feature a large audience of more than 2,000 international participants, including world-renowned experts in autoimmune diseases. The abstract will also be published in Lupus Science & Medicine®, the official journal of the Lupus Foundation of America. The abstract has been selected by an expert committee for oral presentation to showcase the results from Noxopharm's proprietary new class of therapeutics, which are demonstrating promising activity against autoimmune diseases such as lupus. The SofraTM technology platform is based on in-licensed technology from Melbourne's Hudson Institute of Medical Research via Noxopharm's Pharmorage subsidiary. Unlike other anti-inflammatory drugs that target the end-stages of the inflammatory process,
Noxopharm's short nucleic acid sequences, known as oligonucleotides, allow inflammation to be blocked at its source. Sofra oligonucleotides have potential applications in the treatment of excessive inflammatory responses, as seen during infections and in autoimmune diseases. Noxopharm is also actively investigating the potential for its Sofra oligonucleotides to limit the inflammatory side effects associated with mRNA therapeutics and vaccines, and exploring related commercial opportunities.